ClinicalTrials.gg
RecruitingNCT04965220Updated Aug 9, 2023

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HLX 208 in Solid Tumor, sponsored by Shanghai Henlius Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of HLX208 (BRAF V600E inhibitor) in combination with trametinib in patients with advanced solid tumors

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18Y≤Age≤75Y
  • Good Organ Function
  • Expected survival time ≥ 3 months
  • /recurrent advanced BRAF+ solid tumors that have been diagnosed histologically and have failed standard treatment
  • Previous failure to standard treatment, intolerance to standard treatment, absence of standard treatment, or insuitability for standard treatment at this stage.
  • score 0-1;
  • Expected survival time of more than 3 months;

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with BRAF inhibitors or MEK inhibitors
  • Symptomatic brain or meningeal (unless the patient has been on > treatment for 6 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
  • Current or former patients with interstitial lung disease;
  • Active clinical severe infection;
  • A history of other within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
  • Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation therapy (except palliative radiation therapy), may be given during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    ATC

    HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)

    Drug: HLX 208

  • Experimental
    Primary brain tumor

    HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)

    Drug: HLX 208

  • Experimental
    CRC(KRAS mutant)

    HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)

    Drug: HLX 208

  • Experimental
    other solid tumor

    HLX208 (dose of RP2D) and trametinib 2mg qd ,orally,Continuation of treatment until progression, withdrawal of informed consent, intolerant toxicity (whichever occurs first)

    Drug: HLX 208

Interventions

  • take orally

    Also known as: trametinib

06

What researchers measure

Primary outcomes

  1. MTD

    maximum tolerated dose

    Time frame: from first dose to the end of Cycle 1 (each cycle is 21 days)

Secondary outcomes

  1. RP2D

    Recommended dose for phase II clinical trials

    Time frame: from first dose to the end of Cycle 1 (each cycle is 21 days)

  2. Peak Plasma Concentration (Cmax) of HLX208

    pharmacokinetics

    Time frame: from first dose to the beginning of Cycle 4 (each cycle is 21 days)

  3. ORR

    The number of patients with CR or PR divided by the total number of treated patients whose disease was measurable at baseline

    Time frame: from first dose to the last patient was followed up for 6 month

  4. Area under the plasma concentration versus time curve (AUC)of HLX208

    pharmacokinetics

    Time frame: from first dose to the beginning of Cycle 4 (each cycle is 21 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Jun 2024, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jul 16, 2021
StartActual
Jan 5, 2022
Primary completionEst.
Jun 30, 2024
CompletionEst.
Jun 30, 2025
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04965220
Responsible party
Sponsor
First posted
Jul 16, 2021
Start date
Jan 5, 2022
Primary completion
Jun 30, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Aug 9, 2023

Study contacts

Zhang Li, leading PI
Contact
zhangli@sysucc.org.cn
Guo ye, PI
Contact
pattrickguo@gmail.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion